Approximately 5% - 8% of people with Parkinson‘s disease have mutations in the Glucocerebrosidase (GBA) gene. It is supposed that these mutations contribute to the onset of the disease by limiting the ability of GBA to deplete proteins such as alpha-synuclein.
Two SensoLyte® GBA Assay Kits are now available to evaluate GBA enzyme activity.
Red *Fluorimetric* GBA kit is a one-step homogenous assay that is less prone to background interference and ideal for HTS and compound screens
Product Details: Red *Fluorimetric* GBA kit
Blue *Fluorimetric* GBA kit is specifically validated for activator screening
Product Details: Blue *Fluorimetric* GBA kit